The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.
 
Francois P. Duhoux
Consulting or Advisory Role - Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Roche; Teva
 
Agnes Jager
No Relationships to Disclose
 
Luc Dirix
No Relationships to Disclose
 
Manon Thirza Huizing
No Relationships to Disclose
 
Guy Heinrich Maria Jerusalem
Honoraria - Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Novartis; Pfizer; Roche
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Peter Vuylsteke
No Relationships to Disclose
 
Eveline De Cuypere
No Relationships to Disclose
 
Doris Breiner
Employment - Prima BioMed
 
Christian Mueller
Employment - GANYMED Pharmaceuticals; Prima BioMed
Consulting or Advisory Role - Prima BioMed
 
Chrystelle Brignone
Employment - Immutep
Stock and Other Ownership Interests - Prima BioMed
Patents, Royalties, Other Intellectual Property - Prima BioMed
 
Frederic Triebel
Employment - Immutep
Leadership - Immutep
Stock and Other Ownership Interests - Prima BioMed
Patents, Royalties, Other Intellectual Property - Prima BioMed